Clinical value of routine FDG‐PET scans as a decision tool for early immunotherapy discontinuation in advanced melanoma

Eva Ellebaek ◽  
Aimilia Schina ◽  
Rikke Andersen ◽  
Helle Westergren Hendel ◽  
Inge Marie Svane ◽  
2021 ◽  
Vol 32 ◽  
pp. S1407
E. Ellebaek ◽  
M. Donia ◽  
I.M. Svane ◽  
R. Andersen ◽  
H.W. Hendel

2005 ◽  
Vol 38 (19) ◽  
pp. 83

2005 ◽  
Vol 44 (01) ◽  
pp. 8-14 ◽  
B. Dietl ◽  
J. Marienhagen

Summary Aims: An explorative analysis of the diagnostic as well as therapeutic impact of 18F-FDG whole body PET on patients with various tumours in the setting of an university hospital radiation therapy was performed. Patients and methods: 222 FDG PET investigations (148 initial stagings, 74 restagings) in 176 patients with diverse tumour entities (37 lung carcinoma, 15 gastrointestinal tumours, 38 head and neck cancer, 30 lymphoma, 37 breast cancer, 19 sarcoma and 16 other carcinomas) were done. All PET scans were evaluated in an interdisciplinary approach and consecutively confirmed by other imaging modalities or biopsy. Unconfirmed PET findings were ignored. Proportions of verified PET findings, additional diagnostic information (diagnostic impact) and changes of the therapeutic concept intended and documented before PET with special emphasis on radiooncological decisions (therapeutic impact) were analysed. Results: 195/222 (88%) FDG-PET findings were verified, 104/222 (47%) FDG-PET scans yielded additional diagnostic information (38 distant, 30 additional metastasis, 11 local recurrencies, 10 primary tumours and 15 residual tumours after chemoptherapy). The results of 75/222 (34%) scans induced changes in cancer therapy and those of 58/222 (26%) scans induced modifications of radiotherapeutic treatment plan (esp. target volumes). Conclusion: 18F-FDG whole body PET is a valuable diagnostic tool for therapy planning in radiooncology with a high impact on therapeutic decisions in initial staging as well as in restaging. Especially in a curative setting it should be used for definition of target volumes.

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 230
Giulia Ferrarazzo ◽  
Silvia Chiola ◽  
Selene Capitanio ◽  
Maria Isabella Donegani ◽  
Alberto Miceli ◽  

2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (FDG PET/CT) has an established clinical value in the diagnosis and initial staging of multiple myeloma (MM). In the last ten years, a vast body of literature has shown that this tool can also be of high relevance for monitoring therapy responses, making it the recommended imaging approach in this field. Starting from the strengths and weaknesses of radiological imaging in MM, the present review aims to analyze FDG PET/CT’s current clinical value focusing on therapy response assessment and objective interpretation criteria for therapy monitoring. Given the potential occurrence of patients with MM showing non-FDG-avid bone disease, new opportunities can be provided by non-FDG PET tracers. Accordingly, the potential role of non-FDG PET tracers in this setting has also been discussed.

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0125713 ◽  
Takeshi Hara ◽  
Tatsunori Kobayashi ◽  
Satoshi Ito ◽  
Xiangrong Zhou ◽  
Tetsuro Katafuchi ◽  

2012 ◽  
Vol 62 (1) ◽  
pp. 17-25 ◽  
Lotte Engell-Noerregaard ◽  
Helle W. Hendel ◽  
Helle H. Johannesen ◽  
Louise Alslev ◽  
Inge Marie Svane

2013 ◽  
Vol 46 (5) ◽  
pp. 284-289 ◽  
Cássio Miri Oliveira ◽  
Lidia Vasconcellos de Sá ◽  
Thêssa Cristina Alonso ◽  
Teógenes Augusto da Silva

2017 ◽  
Vol 45 (1) ◽  
pp. 258-276 ◽  
Ethan J. Ulrich ◽  
John J. Sunderland ◽  
Brian J. Smith ◽  
Imran Mohiuddin ◽  
Jessica Parkhurst ◽  

2010 ◽  
Vol 28 (11) ◽  
pp. 1896-1903 ◽  
Craig H. Moskowitz ◽  
Heiko Schöder ◽  
Julie Teruya-Feldstein ◽  
Camelia Sima ◽  
Alexia Iasonos ◽  

Purpose In studies of diffuse large B-cell lymphoma, positron emission tomography with [18F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles of chemotherapy has demonstrated prognostic significance. However, some patients treated with immunochemotherapy experience a favorable long-term outcome despite a positive interim FDG-PET scan. To clarify the significance of interim FDG-PET scans, we prospectively studied interim FDG-positive disease within a risk-adapted sequential immunochemotherapy program. Patients and Methods From March 2002 to November 2006, 98 patients at Memorial Sloan-Kettering Cancer Center received induction therapy with four cycles of accelerated R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by an interim FDG-PET scan. If the FDG-PET scan was negative, patients received three cycles of ICE (ifosfamide, carboplatin, and etoposide) consolidation therapy. If residual FDG-positive disease was seen, patients underwent biopsy; if the biopsy was negative, they also received three cycles of ICE. Patients with a positive biopsy received ICE followed by autologous stem-cell transplantation. Results At a median follow-up of 44 months, overall and progression-free survival were 90% and 79%, respectively. Ninety-seven patients underwent interim FDG-PET scans; 59 had a negative scan, 51 of whom are progression free. Thirty-eight patients with FDG-PET–positive disease underwent repeat biopsy; 33 were negative, and 26 remain progression free after ICE consolidation therapy. Progression-free survival of interim FDG-PET–positive/biopsy-negative patients was identical to that in patients with a negative interim FDG-PET scan (P = .27). Conclusion Interim or post-treatment FDG-PET evaluation did not predict outcome with this dose-dense, sequential immunochemotherapy program. Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy.

Sign in / Sign up

Export Citation Format

Share Document